Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of inhaled dry powder hydroxychloroquine local tolerability in healthy volunteers
NL-OMON49136Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by University Medical Center Groningen. Primary endpoints: Local tolerability, Forced expiratory volume in 1 second decrease >15% and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49136.